Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
About this item
Full title
Author / Creator
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this study, mortality from colorectal cancer was reduced by about 80% in a subgroup of patients with tumors that expressed a mutated, activated form of phosphatidylinositol 3-kinase (17% of all tumors) when the patients took aspirin regularly after the diagnosis.
Numerous observational and randomized, controlled studies have suggested a prote...
Alternative Titles
Full title
Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3532946
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3532946
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1207756
